Clinical trials

  • satralizumab for Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
  • ION440 for MECP2 duplication syndrome (MDS)
  • CABA-201 for Systemic lupus erythematosus | Lupus nephritis
  • DURVALUMAB for Muscle-invasive bladder cancer | Urothelial carcinoma (bladder)
  • MB-HUCART19.1 for B-cell precursor acute lymphoblastic leukemia | B-cell non-Hodgkin lymphoma
  • CETRELIMAB for High-risk non-muscle-invasive bladder cancer | Urothelial carcinoma (bladder)
  • DURVALUMAB for Gastric cancer | Gastroesophageal junction adenocarcinoma
  • TSR-022 for Advanced solid tumors
  • ISATUXIMAB for Multiple myeloma|Plasma cell myeloma
  • DB-1303 for Breast cancer (HER2-low, hormone receptor positive, metastatic)
  • ZILOVERTAMAB VEDOTIN for B-cell acute lymphoblastic leukemia|Diffuse large B-cell lymphoma|Burkitt lymphoma|Neuroblastoma|Ewing sarcoma
  • ACP-204 TARTRATE for Alzheimer's disease psychosis